FDA Brief

Warning letters Food

FDA warning letter to

ProHealth Inc.

LowIssued Feb 18, 2021Posted Feb 19, 2021Center for Food Safety and Applied Nutrition (CFSAN)

FDA says ProHealth marketed St. John's Wort Extract as an unapproved drug for depression and anxiety.

What happened

FDA reviewed www.prohealth.com in December 2020 and found that ProHealth takes orders there for Full Spectrum™ St. John's Wort Extract. The website said the product is "Effective for mild to moderate depression" and "Reduces anxiety." FDA said those claims make it a drug, an unapproved new drug, and misbranded because it lacks adequate directions for use.

What FDA found

  1. The website claims the product treats mild to moderate depression and reduces anxiety, which makes it a drug intended to treat disease.

    Section 201(g)(1)(B) of the Act [21 U.S.C. § 321(g)(1)(B)]
  2. The product is a new drug because it is not generally recognized as safe and effective for those uses and has no FDA approval.

    Section 201(p) of the Act [21 U.S.C. § 321(p)]
  3. The product is introduced or delivered for introduction into interstate commerce without the required FDA approval.

    Sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]
  4. The product is misbranded because it lacks adequate directions for use; depression and anxiety are not suitable for self-treatment without a licensed practitioner.

    Section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]; 21 C.F.R. § 201.5
  5. Introducing or delivering the misbranded product into interstate commerce violates the Act.

    Section 301(a) of the Act [21 U.S.C. § 331(a)]

What FDA wants

FDA tells ProHealth to take prompt action to correct the violations and to notify FDA in writing within 15 working days of the steps taken, including how it will prevent recurrence. If it cannot finish in that time, it must explain the delay and give a completion date.

Who should pay attention

  • supplement brands that make disease-treatment claims
  • e-commerce sellers of herbal products
  • labeling and regulatory reviewers for dietary supplement companies

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk